SlideShare a Scribd company logo
1 of 1
Download to read offline
UpdatingandAggregatingLungCancer
PredictionModels
Eoin Gray, Dr. Dawn Teare and Dr. John Stevens
University of Sheffield, School of Health and Related Research
1. Objectives
The research aimed to apply and evaluate
methods to update a single model or aggregate
multiple prediction models.
To achieve this the study had to;
1. Identify methods to update a single
model and aggregate multiple prediction
models that use an IPD.
2. Evaluate the methods practicality and
success when applied to lung cancer pre-
diction models.
3. Assess if an improved lung cancer pre-
diction model could be devised which
could be applied in selective screening
trials.
2. Methods
The methodology of the research was as follows;
1. Apply methods that can update a single prediction model using an external IPD to the
PLCOM2014 lung cancer model.
• The PLCOM2014 Model was selected for its leading performance in an external validation
of epidemiological lung cancer prediction models
2. Apply identified methods to aggregate multiple prediction models to the Bach, Hoggart, Pitts-
burgh and PLCOM2014 models.
• Two versions were conducted including and excluding the Bach Model as this model
limited the size of the IPD available to conduct the meta-modelling.
3. Externally validate the newly devised models in comparison to the original models to assess
if the methods could create a model with an improved performance.
4. Lung Cancer Models
The PLCOM2014 Model was considered for single updating and four models for model aggregation.
Model Never-Smokers Ever-Smokers Age Additional Duration Prediction
PLCOM2014 [4] X X 20+ 6 Years Incidence
Pittsburgh [3] X 6 Years Incidence
Hoggart [2] X 35+ 1(+) Years Incidence/Absolute
Bach [1] X 50-75 30+ PY 1(+) Years Incidence/Absolute
Table 1: Summary of Lung Cancer Prediction Models
The updated PLCOM2014 will predict 6 year risk of incidence for anyone aged 20+ years.
The aggregated model including the Bach Model will predict 6 year risk of incidence in ever-
smokers, aged 50-75, with a minimum 30+ pack year smoking history.
The aggregated model without the Bach Model will predict 6 year risk of incidence in ever-smokers
aged 35+ years.
3. Applied Methods
The literature review identified the following
methods to update the PLCOM2014 Model;
1. Update the intercept
2. Recalibration of the intercept and slope
3. Recalibration and selective re-estimation
4. Re-estimation
5. Re-estimation and extension
6. Selective re-estimation and selective extension
with recalibration
7. Re-estimation and selective extension without
recalibration
The following methods were identified for
model aggregation;
1. Model Averaging
2. Bayesian Model Averaging
• With an without an informative prior
5. Single Updating Results
The methods failed to improve the model dis-
crimination and prediction rules.
The model calibration improved in the internal
validation but struggled externally.
Method AUC Calibration
No Updating 0.7667 0 (823.89)
Recalibration 0.7667 0 (112.04)
Re-Estimation and Extension 0.7671 0 (319.17)
Table 2: External Validation of Leading Methods
Recalibration demonstrated the biggest calibra-
tion improvement.
Re-estimation and extension offered a simi-
lar discrimination and prediction rules to the
PLCOM2014 Model but not an improvement.
No method created an improved model.
6. Aggregating Results
Updating existing models using BMA with an
informative prior created a slightly improved
prediction model.
Model Model Weighting
PLCO 0.50942114
Hoggart 0.49057886
Pittsburgh 6.131e-16
Table 3: Weightings of Improved Model
The models reported a poor calibration.
The AUC marginally improved upon the
original models.
This model was optimal at 1.46% risk threshold
with a sensitivity of 84% and specificity of 36%.
Applying a 15.5% risk threshold would
maintain a specificity of 90% with a sensitivity
around 20%.
8. Conclusions
Single updating methods did not create an im-
proved model [5, 6].
The calibration, discrimination, and prediction
rules were all lower in the external validation
in comparison to the PLCOM2014 Model.
Model averaging and BMA were applied as
model aggregation techniques.
These did not improve the model calibration.
BMA with an informative prior offered a slight
improvement upon the original models.
The final model is a weighting of the Hoggart,
Pittsburgh, and PLCOM2014 models.
Weightings for the final model are in Table 3.
This model is optimal at 1.46% threshold and at
15.5% threshold would maintain a specificity of
90% for a sensitivity around 20%.
Contact Information
Web sheffield.ac.uk/scharr/sections/dts/staff
/eoingray
Email epgray1@sheffield.ac.uk
References
[1] Bach PB et al. Variations in lung cancer risk among
smokers. JNCI. 2003;95(6):470-8.
[2] Hoggart C et al. Cancer Prevention Research.
2012;5(6):834-46.
[3] Wilson DO et al. Lung Cancer. 2015;89(1):31-7
[4] Tammemagi MC et al. PLoS medicine.
2014;11(12):e1001764-e.
[5] Toll, D et al. Journal of Clinical Epidemiology, 61(11),
pp.1085-1094.
[6] Moons K et al. Heart, 98(9), pp.691-698.

More Related Content

What's hot

Nebulized Lidocaine Decreases Discomfort Of Nasogastric Tube Insertion
Nebulized Lidocaine Decreases Discomfort Of Nasogastric Tube InsertionNebulized Lidocaine Decreases Discomfort Of Nasogastric Tube Insertion
Nebulized Lidocaine Decreases Discomfort Of Nasogastric Tube InsertionSrihari Cattamanchi
 
Analysis of kinetic data
Analysis of kinetic dataAnalysis of kinetic data
Analysis of kinetic dataVineetha Menon
 
Population Health Approach for Diabetic Patients with Poor A1c Control
Population Health Approach for Diabetic Patients with Poor A1c ControlPopulation Health Approach for Diabetic Patients with Poor A1c Control
Population Health Approach for Diabetic Patients with Poor A1c ControlPhytel
 
No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...
No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...
No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...Ed J. Hendricks, M.D.
 
Internal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systemsInternal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systemsEvangelos Kontopantelis
 
Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...
Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...
Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...ijtsrd
 
Incorporating data for management of breast cancer
Incorporating data for management of breast cancerIncorporating data for management of breast cancer
Incorporating data for management of breast cancerAjeet Gandhi
 
Personalized Diabetes Management
Personalized Diabetes ManagementPersonalized Diabetes Management
Personalized Diabetes ManagementAshley Odom
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing intervalDr. Ramesh Bhandari
 
Computer software used in PHARMCAY AND PHARMACEUTICAL RESEARCH
Computer software used in PHARMCAY AND PHARMACEUTICAL RESEARCHComputer software used in PHARMCAY AND PHARMACEUTICAL RESEARCH
Computer software used in PHARMCAY AND PHARMACEUTICAL RESEARCHSHWETA patel
 

What's hot (12)

Nebulized Lidocaine Decreases Discomfort Of Nasogastric Tube Insertion
Nebulized Lidocaine Decreases Discomfort Of Nasogastric Tube InsertionNebulized Lidocaine Decreases Discomfort Of Nasogastric Tube Insertion
Nebulized Lidocaine Decreases Discomfort Of Nasogastric Tube Insertion
 
Analysis of kinetic data
Analysis of kinetic dataAnalysis of kinetic data
Analysis of kinetic data
 
Population Health Approach for Diabetic Patients with Poor A1c Control
Population Health Approach for Diabetic Patients with Poor A1c ControlPopulation Health Approach for Diabetic Patients with Poor A1c Control
Population Health Approach for Diabetic Patients with Poor A1c Control
 
No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...
No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...
No Amphetamine-like withdrawal after long-term Phentermine pharmacotherapy fo...
 
Scott Harris
Scott HarrisScott Harris
Scott Harris
 
Internal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systemsInternal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systems
 
Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...
Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...
Analytical Methods Development and Validation of Naproxen and Sumatriptan by ...
 
Incorporating data for management of breast cancer
Incorporating data for management of breast cancerIncorporating data for management of breast cancer
Incorporating data for management of breast cancer
 
Personalized Diabetes Management
Personalized Diabetes ManagementPersonalized Diabetes Management
Personalized Diabetes Management
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing interval
 
Computer software used in PHARMCAY AND PHARMACEUTICAL RESEARCH
Computer software used in PHARMCAY AND PHARMACEUTICAL RESEARCHComputer software used in PHARMCAY AND PHARMACEUTICAL RESEARCH
Computer software used in PHARMCAY AND PHARMACEUTICAL RESEARCH
 
Paras new CV`..
Paras new CV`..Paras new CV`..
Paras new CV`..
 

Similar to Aggregating_Prediction_Models

External_Validation_Prediction_Models
External_Validation_Prediction_ModelsExternal_Validation_Prediction_Models
External_Validation_Prediction_ModelsEoin Gray
 
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptxThe Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptxMMS Holdings
 
Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)
Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)
Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)Bandar AlGhamdi BSRS, MPH-HSQM
 
Bioanalytical method validation guidelines for ligand binding assays
Bioanalytical method validation guidelines for ligand binding assaysBioanalytical method validation guidelines for ligand binding assays
Bioanalytical method validation guidelines for ligand binding assaysSHANE_LOBO145
 
Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Shubham Chinchulkar
 
M10 bioanalytical method validation
M10 bioanalytical method validationM10 bioanalytical method validation
M10 bioanalytical method validationsawantanil
 
A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...
A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...
A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...Shakas Technologies
 
Clinical audit by Dr A. K. Khandelwal
Clinical audit  by Dr A. K. KhandelwalClinical audit  by Dr A. K. Khandelwal
Clinical audit by Dr A. K. KhandelwalDr.Ashok Khandelwal
 
cervix brachytherapy 2
cervix brachytherapy 2cervix brachytherapy 2
cervix brachytherapy 2MsccMohamed
 
2020 trends in biostatistics what you should know about study design - slid...
2020 trends in biostatistics   what you should know about study design - slid...2020 trends in biostatistics   what you should know about study design - slid...
2020 trends in biostatistics what you should know about study design - slid...nQuery
 
On Predicting and Analyzing Breast Cancer using Data Mining Approach
On Predicting and Analyzing Breast Cancer using Data Mining ApproachOn Predicting and Analyzing Breast Cancer using Data Mining Approach
On Predicting and Analyzing Breast Cancer using Data Mining ApproachMasud Rana Basunia
 
Modeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiesModeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiescheweb1
 
Presentation on International Patient Safety Goals (JCI)
Presentation on International Patient Safety Goals (JCI)Presentation on International Patient Safety Goals (JCI)
Presentation on International Patient Safety Goals (JCI)Dr.SONAL GAUR
 
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...Randox
 
DESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDrAniqaSundas
 
RSS 2009 - Investigating the impact of the QOF on quality of primary care
RSS 2009 - Investigating the impact of the QOF on quality of primary careRSS 2009 - Investigating the impact of the QOF on quality of primary care
RSS 2009 - Investigating the impact of the QOF on quality of primary careEvangelos Kontopantelis
 

Similar to Aggregating_Prediction_Models (20)

External_Validation_Prediction_Models
External_Validation_Prediction_ModelsExternal_Validation_Prediction_Models
External_Validation_Prediction_Models
 
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptxThe Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx
 
Microdosing
MicrodosingMicrodosing
Microdosing
 
Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)
Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)
Reducing Radiation Dose in CT Chest for Pulmonary Embolism (P.E) Studies - (QIP)
 
UQME for HSDP
UQME for HSDPUQME for HSDP
UQME for HSDP
 
Bioanalytical method validation guidelines for ligand binding assays
Bioanalytical method validation guidelines for ligand binding assaysBioanalytical method validation guidelines for ligand binding assays
Bioanalytical method validation guidelines for ligand binding assays
 
Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population
 
M10 bioanalytical method validation
M10 bioanalytical method validationM10 bioanalytical method validation
M10 bioanalytical method validation
 
Uncertainty (ASCP)
Uncertainty (ASCP)Uncertainty (ASCP)
Uncertainty (ASCP)
 
A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...
A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...
A Comparative Analysis of Hybridized Genetic Algorithm in Predictive Models o...
 
Method verification
Method verificationMethod verification
Method verification
 
Clinical audit by Dr A. K. Khandelwal
Clinical audit  by Dr A. K. KhandelwalClinical audit  by Dr A. K. Khandelwal
Clinical audit by Dr A. K. Khandelwal
 
cervix brachytherapy 2
cervix brachytherapy 2cervix brachytherapy 2
cervix brachytherapy 2
 
2020 trends in biostatistics what you should know about study design - slid...
2020 trends in biostatistics   what you should know about study design - slid...2020 trends in biostatistics   what you should know about study design - slid...
2020 trends in biostatistics what you should know about study design - slid...
 
On Predicting and Analyzing Breast Cancer using Data Mining Approach
On Predicting and Analyzing Breast Cancer using Data Mining ApproachOn Predicting and Analyzing Breast Cancer using Data Mining Approach
On Predicting and Analyzing Breast Cancer using Data Mining Approach
 
Modeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiesModeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policies
 
Presentation on International Patient Safety Goals (JCI)
Presentation on International Patient Safety Goals (JCI)Presentation on International Patient Safety Goals (JCI)
Presentation on International Patient Safety Goals (JCI)
 
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...
 
DESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptxDESIGN OF DOSAGE REGIMEN.pptx
DESIGN OF DOSAGE REGIMEN.pptx
 
RSS 2009 - Investigating the impact of the QOF on quality of primary care
RSS 2009 - Investigating the impact of the QOF on quality of primary careRSS 2009 - Investigating the impact of the QOF on quality of primary care
RSS 2009 - Investigating the impact of the QOF on quality of primary care
 

Aggregating_Prediction_Models

  • 1. UpdatingandAggregatingLungCancer PredictionModels Eoin Gray, Dr. Dawn Teare and Dr. John Stevens University of Sheffield, School of Health and Related Research 1. Objectives The research aimed to apply and evaluate methods to update a single model or aggregate multiple prediction models. To achieve this the study had to; 1. Identify methods to update a single model and aggregate multiple prediction models that use an IPD. 2. Evaluate the methods practicality and success when applied to lung cancer pre- diction models. 3. Assess if an improved lung cancer pre- diction model could be devised which could be applied in selective screening trials. 2. Methods The methodology of the research was as follows; 1. Apply methods that can update a single prediction model using an external IPD to the PLCOM2014 lung cancer model. • The PLCOM2014 Model was selected for its leading performance in an external validation of epidemiological lung cancer prediction models 2. Apply identified methods to aggregate multiple prediction models to the Bach, Hoggart, Pitts- burgh and PLCOM2014 models. • Two versions were conducted including and excluding the Bach Model as this model limited the size of the IPD available to conduct the meta-modelling. 3. Externally validate the newly devised models in comparison to the original models to assess if the methods could create a model with an improved performance. 4. Lung Cancer Models The PLCOM2014 Model was considered for single updating and four models for model aggregation. Model Never-Smokers Ever-Smokers Age Additional Duration Prediction PLCOM2014 [4] X X 20+ 6 Years Incidence Pittsburgh [3] X 6 Years Incidence Hoggart [2] X 35+ 1(+) Years Incidence/Absolute Bach [1] X 50-75 30+ PY 1(+) Years Incidence/Absolute Table 1: Summary of Lung Cancer Prediction Models The updated PLCOM2014 will predict 6 year risk of incidence for anyone aged 20+ years. The aggregated model including the Bach Model will predict 6 year risk of incidence in ever- smokers, aged 50-75, with a minimum 30+ pack year smoking history. The aggregated model without the Bach Model will predict 6 year risk of incidence in ever-smokers aged 35+ years. 3. Applied Methods The literature review identified the following methods to update the PLCOM2014 Model; 1. Update the intercept 2. Recalibration of the intercept and slope 3. Recalibration and selective re-estimation 4. Re-estimation 5. Re-estimation and extension 6. Selective re-estimation and selective extension with recalibration 7. Re-estimation and selective extension without recalibration The following methods were identified for model aggregation; 1. Model Averaging 2. Bayesian Model Averaging • With an without an informative prior 5. Single Updating Results The methods failed to improve the model dis- crimination and prediction rules. The model calibration improved in the internal validation but struggled externally. Method AUC Calibration No Updating 0.7667 0 (823.89) Recalibration 0.7667 0 (112.04) Re-Estimation and Extension 0.7671 0 (319.17) Table 2: External Validation of Leading Methods Recalibration demonstrated the biggest calibra- tion improvement. Re-estimation and extension offered a simi- lar discrimination and prediction rules to the PLCOM2014 Model but not an improvement. No method created an improved model. 6. Aggregating Results Updating existing models using BMA with an informative prior created a slightly improved prediction model. Model Model Weighting PLCO 0.50942114 Hoggart 0.49057886 Pittsburgh 6.131e-16 Table 3: Weightings of Improved Model The models reported a poor calibration. The AUC marginally improved upon the original models. This model was optimal at 1.46% risk threshold with a sensitivity of 84% and specificity of 36%. Applying a 15.5% risk threshold would maintain a specificity of 90% with a sensitivity around 20%. 8. Conclusions Single updating methods did not create an im- proved model [5, 6]. The calibration, discrimination, and prediction rules were all lower in the external validation in comparison to the PLCOM2014 Model. Model averaging and BMA were applied as model aggregation techniques. These did not improve the model calibration. BMA with an informative prior offered a slight improvement upon the original models. The final model is a weighting of the Hoggart, Pittsburgh, and PLCOM2014 models. Weightings for the final model are in Table 3. This model is optimal at 1.46% threshold and at 15.5% threshold would maintain a specificity of 90% for a sensitivity around 20%. Contact Information Web sheffield.ac.uk/scharr/sections/dts/staff /eoingray Email epgray1@sheffield.ac.uk References [1] Bach PB et al. Variations in lung cancer risk among smokers. JNCI. 2003;95(6):470-8. [2] Hoggart C et al. Cancer Prevention Research. 2012;5(6):834-46. [3] Wilson DO et al. Lung Cancer. 2015;89(1):31-7 [4] Tammemagi MC et al. PLoS medicine. 2014;11(12):e1001764-e. [5] Toll, D et al. Journal of Clinical Epidemiology, 61(11), pp.1085-1094. [6] Moons K et al. Heart, 98(9), pp.691-698.